Anavex Life Sciences Corp (AVXL)

[boi568]

You are assuming that I am discussing a similar buyout premium scenario. I am not. I am discussing an absolute value comparison. I see AVXL, post-PDD Phase 2 success, as similarly valuable to MNTA (at least in the same ballpark). We have the data point on MNTA --$6B over existing cash position. We have the MC data point on AVXL -- a measly $250M. The absolute value of the companies, if they are alike in drug development and size of target market, should be similar. The disconnect, to me, proves AVXL is significantly undervalued, buyout or not.